Krystal Biotech Inc

NASDAQ:KRYS  
59.35
+2.42 (+4.25%)
Products

Jeune Aesthetics Announces Positive Clinical Phase 1 Efficacy Results For KB301, An Investigational Gene-Based Treatment Designed To Address Underlying Biology Of Aging Skin

Published: 03/22/2022 12:13 GMT
Krystal Biotech Inc (KRYS) - Jeune Aesthetics Announces Positive Clinical Phase 1 (pearl-1 Study) Efficacy Results for Kb301, an Investigational Gene-based Treatment Designed to Address Underlying Biology of Aging Skin.
Jeune Aesthetics, Inc- Adverse Events, Associated With Injection Site Reactions, Were Mild and Transitory.
Jeune Aesthetics, Inc- Positive Proof-of-concept Efficacy Data Supports Advancing Into Phase 2 Studies.